BR112015005350A2 - formas sólidas de (s)-2-metoxi-3-{4-[2-(5-metil-2-feniloxazol-4-ila)-etoxi]-benzo[b]tiofen-7-ila}-ácido propiônico e/ou sais do mesmo - Google Patents

formas sólidas de (s)-2-metoxi-3-{4-[2-(5-metil-2-feniloxazol-4-ila)-etoxi]-benzo[b]tiofen-7-ila}-ácido propiônico e/ou sais do mesmo

Info

Publication number
BR112015005350A2
BR112015005350A2 BR112015005350A BR112015005350A BR112015005350A2 BR 112015005350 A2 BR112015005350 A2 BR 112015005350A2 BR 112015005350 A BR112015005350 A BR 112015005350A BR 112015005350 A BR112015005350 A BR 112015005350A BR 112015005350 A2 BR112015005350 A2 BR 112015005350A2
Authority
BR
Brazil
Prior art keywords
thiophen
benzo
ethoxy
methoxy
methyl
Prior art date
Application number
BR112015005350A
Other languages
English (en)
Inventor
Egli André
Stahr Helmut
Faehnrich Karsten
Dreier Lukas
Wyttenbach Nicole
Grassmann Olaf
Mohr Peter
Schwitter Urs
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112015005350A2 publication Critical patent/BR112015005350A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

1/1 resumo formas sólidas de (s)-2-metoxi-3-{4-[2-(5-metil-2-feniloxazol- 4-ila)-etoxi]-benzo[b]tiofen-7-ila}-ácido propiônico e/ou sais do mesmo a presente invenção refere-se a formas sólidas de a de (s)-2-metoxi-3-{4-[2-(5-metil-2-fenil-oxazol-4-ila)etoxi]- benzo[b]tiofen-7-ila}-ácido propiônico e de sais de a de (s)-2-metoxi-3-{4-[2-(5-metil-2-fenil-oxazol-4-ila)etoxi]- benzo[b]tiofen-7-ila}-ácido propiônico.
BR112015005350A 2012-09-12 2013-09-09 formas sólidas de (s)-2-metoxi-3-{4-[2-(5-metil-2-feniloxazol-4-ila)-etoxi]-benzo[b]tiofen-7-ila}-ácido propiônico e/ou sais do mesmo BR112015005350A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12184009 2012-09-12
PCT/EP2013/068561 WO2014040936A1 (en) 2012-09-12 2013-09-09 Solid forms of (s)-2-methoxy-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzo[b]thiophen-7-yl}-propionic acid and of salts thereof

Publications (1)

Publication Number Publication Date
BR112015005350A2 true BR112015005350A2 (pt) 2017-07-04

Family

ID=47044773

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015005350A BR112015005350A2 (pt) 2012-09-12 2013-09-09 formas sólidas de (s)-2-metoxi-3-{4-[2-(5-metil-2-feniloxazol-4-ila)-etoxi]-benzo[b]tiofen-7-ila}-ácido propiônico e/ou sais do mesmo

Country Status (11)

Country Link
US (2) US20150182505A1 (pt)
EP (1) EP2895469B1 (pt)
JP (1) JP2015528476A (pt)
KR (1) KR20150054829A (pt)
CN (1) CN104619689B (pt)
BR (1) BR112015005350A2 (pt)
CA (1) CA2879500A1 (pt)
HK (1) HK1206719A1 (pt)
MX (1) MX2015002095A (pt)
RU (1) RU2015110641A (pt)
WO (1) WO2014040936A1 (pt)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL208074B1 (pl) * 2001-05-15 2011-03-31 Hoffmann La Roche Pochodne oksazolu, sposób ich wytwarzania, środek farmaceutyczny i zastosowanie pochodnych oksazolu
US7262303B2 (en) * 2003-09-29 2007-08-28 Hoffman-La Roche Inc. Process for the production of chiral propionic acid derivatives
ES2397558T3 (es) * 2009-01-23 2013-03-07 F. Hoffmann-La Roche Ag Composición farmacéutica que comprende aleglitazar
US8450496B2 (en) * 2009-03-24 2013-05-28 Hoffman-La Roche Inc. Process for the preparation of propionic acid derivatives
ES2552310T3 (es) * 2009-12-07 2015-11-27 F. Hoffmann-La Roche Ag Proceso para la obtención de derivados de ácido propiónico

Also Published As

Publication number Publication date
WO2014040936A1 (en) 2014-03-20
RU2015110641A (ru) 2016-11-10
KR20150054829A (ko) 2015-05-20
US20150182505A1 (en) 2015-07-02
HK1206719A1 (en) 2016-01-15
CN104619689A (zh) 2015-05-13
MX2015002095A (es) 2015-05-11
EP2895469B1 (en) 2017-10-18
JP2015528476A (ja) 2015-09-28
CN104619689B (zh) 2017-08-08
US20170281602A1 (en) 2017-10-05
CA2879500A1 (en) 2014-03-20
EP2895469A1 (en) 2015-07-22

Similar Documents

Publication Publication Date Title
BR112012032033A2 (pt) novas formas de dosagem de libertação modificada de inibidor de xantina oxidorredutase ou inibidores de xantina oxidase
UY34588A (es) ALGODÓN TOLERANTE A HERBICIDAS EVENTO pDAB4468.19-10.3
HN2012000973A (es) INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA
CL2013001947A1 (es) Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona.
CR20140084A (es) Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2
BR112013023265A2 (pt) artigos absorventes descartáveis com uma camada superior gofrada
CO6551725A2 (es) Dispositivo para la identificación de afecciones orales
BR112012020349A2 (pt) "artigo do vestúario descartavel"
CR20120277A (es) Una forma cristalina y amorfa de genz 112638 hemitartrato como inhibidores de glucosilceramida sintasa
CL2011003191A1 (es) Uso de (6r)-2-amino-4,5,6,7- tetrahidro-6- (propilamino)benzotiazol (dexpramipexol) o sus sales para preparar un medicamento util para tratar la esclerosis lateral amiotrofica.
GT201300258A (es) Derivados de pirazoloespirocetona para uso como inhibidores de acetil-coa carboxilasa
BR112013024423A2 (pt) detecção de doença em plantas
BR112013024099A2 (pt) pegador de mão ergonômico tendo estrias assimétricas
BR112013020536A2 (pt) 1,4-oxazepinas como inibidores de bace1 e/ou bace2
BR112014029012A2 (pt) variantes de quimosina com propriedades melhoradas de coagulação do leite
BR112013029631A2 (pt) "secador de mãos"
UY4153Q (es) Batería
CR20130431A (es) 5-(fenil)/piridinil-etinil)-2-piridina/ 2-pirimidina-carboxamidas como moduladores de mglur5
FR2976522B1 (fr) Pneumatique munis de temoins d'usure sonores multiniveaux
BR112015003957A2 (pt) alfa-1-microglobulina para uso no tratamento de doenças relacionadas com a mitocôndria
UY34295A (es) Nuevo esquema de administración de la n-hidroxi -4- {2-[3- (n,ndimetilaminometil)benzofuran -2- ilcarbonilamino]etoxi}benzamida
CL2015000002A1 (es) Forma de administracion farmaceutica que comprende 5-cloro-n-({(5s)-2-oxo -3-[4-(3-oxo-4-morfolinil)fenil]-1,3-oxazolidin-5-il}metil)-2-tiofencarboxamida; procedimiento de preparacion y uso en la profilaxis y/o tratamiento de trastornos tromboembolicos.
CR20150275A (es) Composición de difenidol de liberación prolongada
BR112012020667A2 (pt) artigo depilatório eficaz
NO20090070L (no) Innretning ved herreundertoy

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law
B07E Notice of approval relating to section 229 industrial property law

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements